Applied BioCode Corporation (TPE:6598)

Market Cap	2.40B -0.8%
Revenue (ttm)	475.20M +38.5%
Net Income	-201.20M
EPS	-1.96
Shares Out	102.81M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	110,607
Average Volume	202,705
Open	23.55
Previous Close	23.55
Day's Range	23.30 - 23.65
52-Week Range	17.00 - 26.00
Beta	0.79
RSI	42.52
Earnings Date	May 11, 2026

About Applied BioCode

Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target using the fluorescence signal intensity. The company develops assays, such as BioCode SARS-CoV-2 Assay, an assay for the detection of SARS-CoV-2 nucleic ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2016
• Country: Cayman Islands
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6598

Financial Performance

In 2025, Applied BioCode's revenue was 475.20 million, an increase of 38.52% compared to the previous year's 343.07 million. Losses were -201.20 million, -22.85% less than in 2024.